| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 132.745 | 191.553 | 319.788 | 393.631 | 406.322 | 392.387 | 716.378 | 735.116 | 542.493 | 382.488 |
| Total Income - EUR | 132.750 | 197.429 | 319.866 | 394.920 | 406.431 | 392.754 | 717.095 | 735.142 | 542.498 | 404.019 |
| Total Expenses - EUR | 125.090 | 125.365 | 217.409 | 185.359 | 150.075 | 156.110 | 247.606 | 245.502 | 224.866 | 215.697 |
| Gross Profit/Loss - EUR | 7.660 | 72.064 | 102.457 | 209.561 | 256.357 | 236.643 | 469.489 | 489.640 | 317.632 | 188.322 |
| Net Profit/Loss - EUR | 6.136 | 60.525 | 98.403 | 205.618 | 252.293 | 232.873 | 463.207 | 484.365 | 312.992 | 178.020 |
| Employees | 1 | 2 | 5 | 5 | 3 | 3 | 4 | 4 | 4 | 3 |
Check the financial reports for the company - Eligon Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 14.771 | 24.138 | 61.661 | 58.141 | 50.768 | 131.461 | 207.533 | 359.688 | 449.629 | 605.700 |
| Current Assets | 58.067 | 128.132 | 120.931 | 369.711 | 492.568 | 685.709 | 994.199 | 1.288.720 | 1.126.755 | 1.033.913 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 8.120 | 1.941 | 26.723 | 64.909 | 66.557 |
| Receivables | 12.111 | 45.918 | 44.835 | 83.195 | 85.912 | 115.562 | 110.300 | 183.543 | 1.041.300 | 219.296 |
| Cash | 45.956 | 82.214 | 76.096 | 286.517 | 406.657 | 562.028 | 881.958 | 1.078.454 | 20.547 | 44.444 |
| Shareholders Funds | 8.350 | 68.790 | 98.456 | 288.213 | 534.924 | 757.656 | 1.150.864 | 490.021 | 801.527 | 875.316 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 64.488 | 90.834 | 84.137 | 139.640 | 8.412 | 59.514 | 50.868 | 1.158.386 | 698.975 | 688.839 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75.882 | 75.458 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Eligon Pharma Srl